Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey

Xenobiotica

Volumn 41, Issue 5, 2011, Pages 430-436

  Kuhlmann, Olaf ^a   Heinig, Katja ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Absorption; cholesteryl ester transfer protein; dalcetrapib S glucuronide; dalcetrapib S methyl; firstpass metabolism; glucuronidation; intestinal bioavailability; portal cannulation

Indexed keywords

DALCETRAPIB; DALCETRAPIB S GLUCURONIDE; DALCETRAPIB S METHYL; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL CATHETERIZATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG STRUCTURE; FIRST PASS EFFECT; HAPLORHINI; INTESTINE WALL; MALE; MAXIMUM PLASMA CONCENTRATION; METHYLATION; NONHUMAN; PORTAL VEIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AREA UNDER CURVE; MACACA FASCICULARIS; MALE; SULFHYDRYL COMPOUNDS;

MACACA FASCICULARIS; PRIMATES;

EID: 79954490677     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.551223     Document Type: Article

References (11)

1. Derks M, Abt M, Phelan M, Turnbull L, Meneses-Lorente G, Bech N, White AM, Parr G. (2010a). Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 50:1188-1201.
2. Derks M, Busse-Reid R, Kuhlmann O, Paehler A. (2010b). [ 14C]- Dalcetrapib ADME following a single oral dose in healthy male subjects. Clin Pharmacol Ther 87 (S9):S37 (abstract).
3. Derks M, Fowler S, Kuhlmann O. (2009a). In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 25:891-902.
4. Derks M, Fowler S, Kuhlmann O. (2009b). A single-center, openlabel, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther 31:586-599.
5. Kastelein JJ, Duivenvoorden R, Deanfield J, de Groot E, Jukema JW, Kaski JC, Münzel T, Taddei S, Lehnert V, Burgess T, Kallend D, Lüscher TF. (2011). Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr Med Res Opin 27:141-150.
6. Kunta JR, Lee SH, Perry BA, Lee YH, Sinko PJ. (2004). Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits. Drug Metab Dispos 32:1293-1298. (Pubitemid 39410915)
7. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. (2000). A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203-207. (Pubitemid 30469005)
8. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. (2009). Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 158:896-901.
9. Stein EA, Stroes ES, Steiner G, Buckley BM, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJ. (2009). Safety and tolerability of dalcetrapib. Am J Cardiol 104:82-91.
10. Ward KW, Proksch JW, Levy MA, Smith BR. (2001). Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics. Drug Metab Dispos 29:82-88. (Pubitemid 32041684)
11. Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, Smith BR. (2004). Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 32:172-177. (Pubitemid 38176933)